Amgen Backs New $315M Life Sciences Fund

Thousand Oaks-based Amgen has helped to back a new, life sciences fund, managed by San Francisco-based venBio, as an anchor supporter of a new fund. venBio said Friday that it has closed a $315M life sciences fund, venBio Global Strategic Fund II, which was anchored by Amgen, Merck, and Baxalta, and also included other Limited Partners. venBio did not say how much Amgen committed to the fund, which is venBio's second life sciences fund. venBio is focused on funding medicines and technologies with a focus on novel therapeutics for unmet medical needs.